PMID- 34941464
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220531
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 31
IP  - 1
DP  - 2022 Jan
TI  - New treatment approaches for Alzheimer's disease: preclinical studies and 
      clinical trials centered on antidiabetic drugs.
PG  - 105-123
LID - 10.1080/13543784.2022.2022122 [doi]
AB  - INTRODUCTION: Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) 
      represent two major chronic diseases that affect a large percentage of the 
      population and share common pathogenetic mechanisms, including oxidative stress 
      and inflammation. Considering their common mechanistic aspects, and given the 
      current lack of effective therapies for AD, accumulating research has focused on 
      the therapeutic potential of antidiabetic drugs in the treatment or prevention of 
      AD. AREAS COVERED: This review examines the latest preclinical and clinical 
      evidence on the potential of antidiabetic drugs as candidates for AD treatment. 
      Numerous approved drugs for T2DM, including insulin, metformin, glucagon-like 
      peptide-1 receptor agonists (GLP-1 RA), and sodium glucose cotransporter 2 
      inhibitors (SGLT2i), are in the spotlight and may constitute novel approaches for 
      AD treatment. EXPERT OPINION: Among other pharmacologic agents, GLP-1 RA and 
      SGLT2i have so far exhibited promising results as novel treatment approaches for 
      AD, while current research has centered on deciphering their action on the 
      central nervous system (CNS). Further investigation is crucial to reveal the most 
      effective pharmacological agents and their optimal combinations, maximize their 
      beneficial effects on neurons, and find ways to increase their distribution to 
      the CNS.
FAU - Katsenos, Andreas P
AU  - Katsenos AP
AD  - Department of Physiology, Faculty of Medicine, School of Health Sciences, 
      University of Ioannina, Ioannina, Greece.
AD  - Nanomedicine and Nanobiotechnology Research Group, University of Ioannina, 
      Greece.
FAU - Davri, Athena S
AU  - Davri AS
AD  - Department of Physiology, Faculty of Medicine, School of Health Sciences, 
      University of Ioannina, Ioannina, Greece.
FAU - Simos, Yannis V
AU  - Simos YV
AUID- ORCID: 0000-0003-1764-8906
AD  - Department of Physiology, Faculty of Medicine, School of Health Sciences, 
      University of Ioannina, Ioannina, Greece.
AD  - Nanomedicine and Nanobiotechnology Research Group, University of Ioannina, 
      Greece.
FAU - Nikas, Ilias P
AU  - Nikas IP
AD  - School of Medicine, European University Cyprus, Nicosia, Cyprus.
FAU - Bekiari, Chryssa
AU  - Bekiari C
AD  - Laboratory of Anatomy and Histology, school of Veterinary Medicine, Faculty of 
      Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Paschou, Stavroula A
AU  - Paschou SA
AD  - Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, 
      Alexandra Hospital, School of Medicine, National and Kapodistrian University of 
      Athens, Athens, Greece.
FAU - Peschos, Dimitrios
AU  - Peschos D
AUID- ORCID: 0000-0002-5490-0755
AD  - Department of Physiology, Faculty of Medicine, School of Health Sciences, 
      University of Ioannina, Ioannina, Greece.
AD  - Nanomedicine and Nanobiotechnology Research Group, University of Ioannina, 
      Greece.
FAU - Konitsiotis, Spyridon
AU  - Konitsiotis S
AD  - Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.
FAU - Vezyraki, Patra
AU  - Vezyraki P
AD  - Department of Physiology, Faculty of Medicine, School of Health Sciences, 
      University of Ioannina, Ioannina, Greece.
FAU - Tsamis, Konstantinos I
AU  - Tsamis KI
AUID- ORCID: 0000-0002-7032-1630
AD  - Department of Physiology, Faculty of Medicine, School of Health Sciences, 
      University of Ioannina, Ioannina, Greece.
AD  - Nanomedicine and Nanobiotechnology Research Group, University of Ioannina, 
      Greece.
AD  - Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220102
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - *Alzheimer Disease/drug therapy
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology
OTO - NOTNLM
OT  - Alzheimer disease
OT  - GLP-1 receptor agonists
OT  - SGLT2 inhibitors
OT  - T2DM
OT  - antidiabetics
OT  - b-amyloid
OT  - hippocampus
OT  - insulin
OT  - metformin
OT  - neuroprotection
EDAT- 2021/12/24 06:00
MHDA- 2022/02/26 06:00
CRDT- 2021/12/23 17:16
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2021/12/23 17:16 [entrez]
AID - 10.1080/13543784.2022.2022122 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2022 Jan;31(1):105-123. doi: 
      10.1080/13543784.2022.2022122. Epub 2022 Jan 2.